Evidence map›Paper›PMID 32019285›Full record

ArticleCancer research and treatment2020

CXCL-13 Regulates Resistance to 5-Fluorouracil in Colorectal Cancer.

Guolin Zhang, Xin Luo, Wei Zhang, Engeng Chen, Jianbin Xu, Fei Wang, Gaoyang Cao, Zhenyu Ju, Dongai Jin, Xuefeng Huang and 2 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research and treatment, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 53 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. TIMP-2 as a predictive biomarker in 5-Fu-resistant colorectal cancer.Journal of cancer research and clinical oncology · 2023
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Exosomes-mediated tumor treatment: One body plays multiple roles.Asian journal of pharmaceutical sciences · 2022
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Guolin ZhangDepartment of Colorectal Surgery, Sir Run Run Shaw Hospital of Zhejiang University, Hangzhou, China.
Xin LuoDepartment of Colorectal Surgery, Sir Run Run Shaw Hospital of Zhejiang University, Hangzhou, China.
Wei ZhangDepartment of Colorectal Surgery, Sir Run Run Shaw Hospital of Zhejiang University, Hangzhou, China.
Engeng ChenDepartment of Colorectal Surgery, Sir Run Run Shaw Hospital of Zhejiang University, Hangzhou, China.
Jianbin XuZhejiang Province Key Laboratory of Biological Treatment, Hangzhou, China.
Fei WangDepartment of Colorectal Surgery, Sir Run Run Shaw Hospital of Zhejiang University, Hangzhou, China.
Gaoyang CaoDepartment of Colorectal Surgery, Sir Run Run Shaw Hospital of Zhejiang University, Hangzhou, China.
Zhenyu JuKey Laboratory of Regenerative Medicine of Ministry of Education, Institute of Aging and Regenerative Medicine, Jinan University, Guangzhou, China.
Dongai JinDepartment of Colorectal Surgery, Sir Run Run Shaw Hospital of Zhejiang University, Hangzhou, China.
Xuefeng HuangDepartment of Colorectal Surgery, Sir Run Run Shaw Hospital of Zhejiang University, Hangzhou, China.
Wei ZhouDepartment of Colorectal Surgery, Sir Run Run Shaw Hospital of Zhejiang University, Hangzhou, China.
Zhangfa SongDepartment of Colorectal Surgery, Sir Run Run Shaw Hospital of Zhejiang University, Hangzhou, China.
Sir Run Run Shaw Hospital · CNZhejiang University · CNBlood Center of Zhejiang Province · CNJinan University · CN

Funding

Department of Health of Zhejiang Province 2018KY473,2018PY0250National Natural Science Foundation of China 81771502, 81701820Natural Science Foundation of Zhejiang Province LH19H160001
6 · The paper itself

Abstract

purpose5-Fluorouracil (5-Fu) is used as a conventional chemotherapy drug in chemotherapy for patients with advanced colorectal cancer, but many patients still suffer from treatment failure due to 5-Fu resistance. Emerging observations revealed the important role of chemokine (C-X-C motif) ligand 13 (CXCL-13) in tumor microenvironment and its relationship with prognosis in patients with colorectal cancer. This study is designed to reveal the important role of CXCL-13 in causing colorectal cancer resistance to 5-Fu. MATERIALS AND

methodsCXCL-13 levels of patient's serum or cell culture supernatants were measured separately by enzyme-linked immunosorbent assay. In cell assays, cell viability is detected by Cell Counting Kit-8. Therefore, the recombinant human CXCL-13 was used to simulate its high expression in cells while its antibody and siRNA were used to reduce CXCL-13 expression in cells.

resultsIn this study, we demonstrated that CXCL-13 is associated with 5-Fu resistance by culture medium exchange experiments and cytokine arrays of colorectal cancer resistant and nonresistant cells. Clinical studies showed that CXCL-13 is highly expressed in the serum of 5-Fu-resistant patients. High levels of serum CXCL-13 also predict a worse clinical outcome. The addition of recombinant CXCL-13 cytokine resulted in 5-Fu resistance, while its antibody overcame 5-Fu resistance, and knockdown of CXCL-13 expression by siRNA also reduced 5-Fu resistance, which can be saved by added recombination CXCL-13.

conclusionThese results not only identify a CXCL-13 mediated 5-Fu resistance mechanism but also provide a novel target for 5-Fu-resistant colorectal cancer in prevention and treatment strategies.

Indexed as

AgedAnimalsChemokine CXCL13Colorectal NeoplasmsDrug Resistance, NeoplasmFemaleFluorouracilHumansMiceMiddle AgedChemokine CXCL13Cxcl13 protein, mouseFluorouracil5-FluorouracilChemokinesColorectal neoplasmsCXCL13Drug resistance

Identifiers

PMID32019285
PMCPMC7176956
OpenAlexW2996789446

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.